Last $2.84 USD
Change Today +0.106 / 3.88%
Volume 6.1K
As of 1:22 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

biocept inc (BIOC) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/5/14 - $10.02
52 Week Low
10/1/14 - $2.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOCEPT INC (BIOC)

Related News

No related news articles were found.

biocept inc (BIOC) Related Businessweek News

No Related Businessweek News Found

biocept inc (BIOC) Details

Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company is also developing other OncoCEE CTC tests, including OncoCEE-LU for lung cancer; OncoCEE-GA for gastric cancer; OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma. Biocept, Inc. sells its products through its direct sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States, as well as biopharma companies. It has collaboration agreement with Rosetta Genomics, Ltd. to evaluate microRNAs from circulating tumor cells. The company was founded in 1997 and is headquartered in San Diego, California.

27 Employees
Last Reported Date: 03/28/14
Founded in 1997

biocept inc (BIOC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $66.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $227.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $208.2K
Compensation as of Fiscal Year 2013.

biocept inc (BIOC) Key Developments

Biocept, Inc. and Rosetta Genomics, Ltd. Collaborate to Evaluate microRNAs From Circulating Tumor Cells

Biocept, Inc. and Rosetta Genomics, Ltd. announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers. This joint proof-of-concept study will initially seek to determine whether CTCs from lung cancers provide microRNA signatures similar to those previously demonstrated by Rosetta and in use clinically from tissue sample testing performed through Rosetta's CLIA laboratory. Biocept's proprietary microfluidic channel technology will be utilized to capture CTCs in the blood. Rosetta Genomics will then deploy its proprietary RT-PCR platform to characterize microRNAs isolated from those CTCs. The goal of this project is to demonstrate proof-of-concept and determine opportunities for next steps in development of advanced diagnostics. This could include the development of next generation versions of certain current tests, which would then use CTCs from blood as "liquid biopsies" in lieu of current invasive approaches. With proof-of-concept data, the joint platform could be of value to pharmaceutical and biotech companies searching for a way to use liquid biopsies/CTCs along with microRNA profiling (and other downstream modalities like Next Generation Sequencing mutational profiles) to predict and monitor response to therapies. Analysis of CTCs provides the ability to obtain genomic information from patients where tissue biopsies are not practical or possible. A simple blood draw allows the study of tumor cells in circulation on a real-time basis starting with the point-of-diagnosis and continuing throughout treatment. For example, this provides valuable insights when a patient's disease progresses while on therapy due to emerging resistance, thus allowing the clinician to potentially plot the optimal next course of treatment. MicroRNA analysis can provide unique insight into the biomarker profiles of these cells. Combining current and new microRNA profiles through the use of CTC capture could expand the role and utility of microRNA signatures in various solid tumor diseases.

Biocept Expands Collaboration with MD Anderson Cancer Center

Biocept, Inc. announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer. The continuation of this collaboration follows the recent findings from an MD Anderson mouse model study published in the peer-reviewed medical journal, Cancer Cell in which Biocept's OncoCEE testing was utilized. The Company's OncoCEE microfluidic device captures CTCs and then evaluates the genomic marker, HER3 (human epidermal growth factor receptor 3), for expression on ovarian cancer cells in order to better understand alternative routes of metastasis.

Biocept, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 10:00 AM

Biocept, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 10:00 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Michael W. Nall, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $2.84 USD +0.106

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.04 USD +0.03
BioMerieux €77.78 EUR +0.80
Daiichi Sankyo Co Ltd ¥1,600 JPY -41.50
Fluidigm Corp $26.73 USD +0.91
Illumina Inc $179.50 USD +15.03
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 140.9x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at